Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Nuclear Cardiology
Published in: Journal of Nuclear Cardiology 4/2013

01-08-2013 | An ASNC 20th Anniversary Article

Noninvasive assessment myocardial viability: Current status and future directions

Author: Kevin C. Allman, MBBS, FRACP, FACC, FCSANZ, FAANMS, FASNC

Published in: Journal of Nuclear Cardiology | Issue 4/2013

Login to get access

Abstract

Observations of reversibility of cardiac contractile dysfunction in patients with coronary artery disease and ischemia were first made more than 40 years ago. Since that time a wealth of basic science and clinical data has been gathered exploring the mechanisms of this phenomenon of myocardial viability and relevance to clinical care of patients. Advances in cardiac imaging techniques have contributed greatly to knowledge in the area, first with thallium-201 imaging, then later with Tc-99m-based tracers for SPECT imaging and metabolic tracers used in conjunction with positron emission tomography (PET), most commonly F-18 FDG in conjunction with blood flow imaging with N-13 ammonia or Rb-82 Cl. In parallel, stress echocardiography has made great progress also. Over time observational studies in patients using these techniques accumulated and were later summarized in several meta-analyses. More recently, cardiac magnetic resonance imaging (CMR) has contributed further information in combination with either late gadolinium enhancement imaging or dobutamine stress. This review discusses the tracer and CMR imaging techniques, the pooled observational data, the results of clinical trials, and ongoing investigation in the field. It also examines some of the current challenges and issues for researchers and explores the emerging potential of combined PET/CMR imaging for myocardial viability.
Literature
1.
Emond M, Mock MB, Davis KB, et al. Long-term survival of medically treated patients in the coronary artery surgery study (CASS) registry. Circulation 1994;90:2645-57.PubMedCrossRef
2.
Sharir T, Germano G, Kang X, et al. Prediction of myocardial infarction versus cardiac death by gated myocardial perfusion SPECT: Risk stratification by the amount of stress-induced ischemia and the poststress ejection fraction. J Nucl Med 2001;42:831-7.PubMed
3.
Saltiel J, Lesperance J, Bourassa MG, Castonguay Y, Campeau L, Grondin P. Reversibility of left ventricular dysfunction following aorto-coronary by-pass grafts. Am Journal Roentgenol Radium Ther Nucl Med 1970;110:739-46.CrossRef
4.
Chatterjee K, Swan HJ, Parmley WW, Sustaita H, Marcus H, Matloff J. Depression of left ventricular function due to acute myocardial ischemia and its reversal after aortocoronary saphenous-vein bypass. N Engl J Med 1972;286:1117-22.PubMedCrossRef
5.
Chatterjee K, Swan HJ, Parmley WW, Sustaita H, Marcus HS, Matloff J. Influence of direct myocardial revascularization on left ventricular asynergy and function in patients with coronary heart disease with and without previous myocardial infarction. Circulation 1973;47:276-86.PubMedCrossRef
6.
Heyndrickx GR, Millard RW, McRitchie RJ, Maroko PR, Vatner SF. Regional myocardial functional and electrophysiological alterations after brief coronary artery occlusion in conscious dogs. J Clin Investig 1975;56:978-85.PubMedCrossRef
7.
Heyndrickx GR, Baig H, Nellens P, Leusen I, Fishbein MC, Vatner SF. Depression of regional blood flow and wall thickening after brief coronary occlusions. Am J Physiol 1978;234:H653-9.PubMed
8.
DeBoer LW, Ingwall JS, Kloner RA, Braunwald E. Prolonged derangements of canine myocardial purine metabolism after a brief coronary artery occlusion not associated with anatomic evidence of necrosis. Proc Natl Acad Sci USA 1980;77:5471-5.PubMedCrossRef
9.
Braunwald E, Kloner RA. The stunned myocardium: prolonged, postischemic ventricular dysfunction. Circulation 1982;66:1146-9.PubMedCrossRef
10.
Kloner RA, Ellis SG, Lange R, Braunwald E. Studies of experimental coronary artery reperfusion. Effects on infarct size, myocardial function, biochemistry, ultrastructure and microvascular damage. Circulation 1983;68:8-15.
11.
Diamond GA, Forrester JS, deLuz PL, Wyatt HL, Swan HJ. Post-extrasystolic potentiation of ischemic myocardium by atrial stimulation. Am Heart J 1978;95:204-9.PubMedCrossRef
12.
Rahimtoola SH. A perspective on the three large multicenter randomized clinical trials of coronary bypass surgery for chronic stable angina. Circulation 1985;72:V123-35.PubMedCrossRef
13.
14.
Elsasser A, Schlepper M, Klovekorn WP, et al. Hibernating myocardium: An incomplete adaptation to ischemia. Circulation 1997;96:2920-31.PubMedCrossRef
15.
Allman KC, Wieland DM, Muzik O, Degrado TR, Wolfe ER Jr, Schwaiger M. Carbon-11 hydroxyephedrine with positron emission tomography for serial assessment of cardiac adrenergic neuronal function after acute myocardial infarction in humans. J Am Coll Cardiol 1993;22:368-75.PubMedCrossRef
16.
Canty JM Jr, Fallavollita JA. Chronic hibernation and chronic stunning: A continuum. J Nucl Cardiol 2000;7:509-27.PubMedCrossRef
17.
Fallavollita JA, Logue M, Canty JM Jr. Stability of hibernating myocardium in pigs with a chronic left anterior descending coronary artery stenosis: Absence of progressive fibrosis in the setting of stable reductions in flow, function and coronary flow reserve. J Am Coll Cardiol 2001;37:1989-95.PubMedCrossRef
18.
Canty JM Jr, Suzuki G, Banas MD, Verheyen F, Borgers M, Fallavollita JA. Hibernating myocardium: Chronically adapted to ischemia but vulnerable to sudden death. Circ Res 2004;94:1142-9.PubMedCrossRef
19.
20.
Fallavollita JA, Riegel BJ, Suzuki G, Valeti U, Canty JM Jr. Mechanism of sudden cardiac death in pigs with viable chronically dysfunctional myocardium and ischemic cardiomyopathy. Am J Physiol Heart Circ Physiol 2005;289:H2688-96.PubMedCrossRef
21.
Fallavollita JA, Luisi AJ Jr, Michalek SM, et al. Prediction of arrhythmic events with positron emission tomography: PAREPET study design and methods. Contemp Clin Trials 2006;27:374-88.PubMedCrossRef
22.
Fallavollita J, Heavey BM, Baldwa S et al. Volume of denervated myocardium is a novel predictor of VT/VF: Prediction of arrhythmic events with positron emission tomography (PAREPET) study. Heart Rhythm J 2012;9:1578.
23.
Hunt SA, Abraham WT, Chin MH, et al. 2009 Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009;53:e1-90.PubMedCrossRef
24.
Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA guideline for coronary artery bypass graft surgery. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons. J Am Coll Cardiol 2011;58:e123-210.PubMedCrossRef
25.
The task force on myocardial revascularization of the European Society of Cardiology (ECS) and the European Association for Cardio-thoracic Surgery (EACTS) (Wijns W, Chair). Guidelines on myocardial revascularization. Eur Heart J 2010;31:2501-55.
26.
Patel MR, White RD, Abbara S et al. ACCF/ACR/ASE/ASNC/SCCT/SCMR appropriate utilization of cardiovascular imaging in heart failure: A joint report of the American College of Radiology Appropriateness Criteria Committee and the American College of Cardiology Foundation Appropriate Use Criteria Task Force. J Am Coll Cardiol 2013;61:2207-31.
27.
Tillisch J, Brunken R, Marshall R, et al. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med 1986;314:884-8.PubMedCrossRef
28.
Cornel JH, Bax JJ, Elhendy A, et al. Agreement and disagreement between “metabolic viability” and “contractile reserve” in akinetic myocardium. J Nucl Cardiol 1999;6:383-8.PubMedCrossRef
29.
Schmidt M, Voth E, Schneider CA, et al. F-18-FDG uptake is a reliable predictory of functional recovery of akinetic but viable infarct regions as defined by magnetic resonance imaging before and after revascularization. Magn Reson Imaging 2004;22:229-36.PubMedCrossRef
30.
Beanlands RS, Ruddy TD, deKemp RA, et al. Positron emission tomography and recovery following revascularization (PARR-1): The importance of scar and the development of a prediction rule for the degree of recovery of left ventricular function. J Am Coll Cardiol 2002;40:1735-43.PubMedCrossRef
31.
Bax JJ, Schinkel AF, Boersma E et al. Early versus delayed revascularization in patients with ischemic cardiomyopathy and substantial viability: impact on outcome. Circulation 2003;108:II39-42.
32.
Beanlands RS, Nichol G, Huszti E, et al. F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: A randomized, controlled trial (PARR-2). J Am Coll Cardiol 2007;50:2002-12.PubMedCrossRef
33.
Ling LF, Marwick TH, Flores DR et al. Identification of Therapeutic benefit from revascularization in patients with left ventricular systolic dysfunction: Inducible ischemia versus hibernating myocardium. Circ Cardiovasc Imaging 2013.
34.
Desideri A, Cortigiani L, Christen AI, et al. The extent of perfusion-F18-fluorodeoxyglucose positron emission tomography mismatch determines mortality in medically treated patients with chronic ischemic left ventricular dysfunction. J Am Coll Cardiol 2005;46:1264-9.PubMedCrossRef
35.
D’Egidio G, Nichol G, Williams KA, et al. Increasing benefit from revascularization is associated with increasing amounts of myocardial hibernation: A substudy of the PARR-2 trial. JACC Cardiovasc Imaging 2009;2:1060-8.PubMedCrossRef
36.
37.
Wall BF, Haylock R, Jansen JTM, Hillier MC, Hart D, Shrimpton DC. Radiation risks from medical X-ray examinations as a function of the age and sex of the patient. Chilton: HPA Centre for Radiation, Chemical and Environmental Hazards; 2011. p. 1-66.
38.
Chareonthaitawee P, Gersh BJ, Araoz PA, Gibbons RJ. Revascularization in severe left ventricular dysfunction: The role of viability testing. J Am Coll Cardiol 2005;46:567-74.PubMedCrossRef
39.
Arai AE. The cardiac magnetic resonance (CMR) approach to assessing myocardial viability. J Nucl Cardiol 2011;18:1095-102.PubMedCrossRef
40.
Kim RJ, Wu E, Rafael A, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 2000;343:1445-53.PubMedCrossRef
41.
Kim RJ, Chen EL, Lima JA, Judd RM. Myocardial Gd-DTPA kinetics determine MRI contrast enhancement and reflect the extent and severity of myocardial injury after acute reperfused infarction. Circulation 1996;94:3318-26.PubMedCrossRef
42.
Kim RJ, Fieno DS, Parrish TB, et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation 1999;100:1992-2002.PubMedCrossRef
43.
Klein C, Nekolla SG, Bengel FM, et al. Assessment of myocardial viability with contrast-enhanced magnetic resonance imaging: Comparison with positron emission tomography. Circulation 2002;105:162-7.PubMedCrossRef
44.
Knuesel PR, Nanz D, Wyss C, et al. Characterization of dysfunctional myocardium by positron emission tomography and magnetic resonance: Relation to functional outcome after revascularization. Circulation 2003;108:1095-100.PubMedCrossRef
45.
Selvanayagam JB, Kardos A, Francis JM, et al. Value of delayed-enhancement cardiovascular magnetic resonance imaging in predicting myocardial viability after surgical revascularization. Circulation 2004;110:1535-41.PubMedCrossRef
46.
Gerber BL, Rousseau MF, Ahn SA, et al. Prognostic value of myocardial viability by delayed-enhanced magnetic resonance in patients with coronary artery disease and low ejection fraction: Impact of revascularization therapy. J Am Coll Cardiol 2012;59:825-35.PubMedCrossRef
47.
Bello D, Shah DJ, Farah GM, et al. Gadolinium cardiovascular magnetic resonance predicts reversible myocardial dysfunction and remodeling in patients with heart failure undergoing beta-blocker therapy. Circulation 2003;108:1945-53.PubMedCrossRef
48.
Matsumoto H, Matsuda T, Miyamoto K, Shimada T, Mikuri M, Hiraoka Y. Peri-infarct zone on early contrast-enhanced CMR imaging in patients with acute myocardial infarction. JACC Cardiovasc Imaging 2011;4:610-8.PubMedCrossRef
49.
Baer FM, Theissen P, Schneider CA, et al. Dobutamine magnetic resonance imaging predicts contractile recovery of chronically dysfunctional myocardium after successful revascularization. J Am Coll Cardiol 1998;31:1040-8.PubMedCrossRef
50.
Nijveldt R, Hofman MB, Hirsch A, et al. Assessment of microvascular obstruction and prediction of short-term remodeling after acute myocardial infarction: Cardiac MR imaging study. Radiology 2009;250:363-70.PubMedCrossRef
51.
Kwong RY, Chan AK, Brown KA, et al. Impact of unrecognized myocardial scar detected by cardiac magnetic resonance imaging on event-free survival in patients presenting with signs or symptoms of coronary artery disease. Circulation 2006;113:2733-43.PubMedCrossRef
52.
Schelbert EB, Cao JJ, Sigurdsson S, et al. Prevalence and prognosis of unrecognized myocardial infarction determined by cardiac magnetic resonance in older adults. JAMA 2012;308:890-6.PubMedCrossRef
53.
Kirschbaum SW, Rossi A, Boersma E, et al. Combining magnetic resonance viability variables better predicts improvement of myocardial function prior to percutaneous coronary intervention. Int J Cardiol 2012;159:192-7.PubMedCrossRef
54.
Roes SD, Kaandorp TA, Marsan NA, et al. Agreement and disagreement between contrast-enhanced magnetic resonance imaging and nuclear imaging for assessment of myocardial viability. Eur J Nucl Med Mol Imaging 2009;36:594-601.PubMedCrossRef
55.
Patterson RE, Sigman SR, O’Donnell RE, Eisner RL. Viability assessment with MRI is superior to FDG-PET for viability: Con. J Nucl Cardiol 2010;17:298-309.PubMedCrossRef
56.
Wellnhofer E, Olariu A, Klein C, et al. Magnetic resonance low-dose dobutamine test is superior to SCAR quantification for the prediction of functional recovery. Circulation 2004;109:2172-4.PubMedCrossRef
57.
Samady H, Elefteriades JA, Abbott BG, Mattera JA, McPherson CA, Wackers FJ. Failure to improve left ventricular function after coronary revascularization for ischemic cardiomyopathy is not associated with worse outcome. Circulation 1999;100:1298-304.PubMedCrossRef
58.
Bax JJ, Cornel JH, Visser FC, et al. Prediction of improvement of contractile function in patients with ischemic ventricular dysfunction after revascularization by fluorine-18 fluorodeoxyglucose single-photon emission computed tomography. J Am Coll Cardiol 1997;30:377-83.PubMedCrossRef
59.
Flameng W, Suy R, Schwarz F, et al. Ultrastructural correlates of left ventricular contraction abnormalities in patients with chronic ischemic heart disease: Determinants of reversible segmental asynergy postrevascularization surgery. Am Heart J 1981;102:846-57.PubMedCrossRef
60.
Marwick TH, MacIntyre WJ, Lafont A, Nemec JJ, Salcedo EE. Metabolic responses of hibernating and infarcted myocardium to revascularization. A follow-up study of regional perfusion, function, and metabolism. Circulation 1992;85:1347-53.PubMedCrossRef
61.
Gerber BL, Vanoverschelde JL, Bol A, et al. Myocardial blood flow, glucose uptake, and recruitment of inotropic reserve in chronic left ventricular ischemic dysfunction. Implications for the pathophysiology of chronic myocardial hibernation. Circulation 1996;94:651-9.PubMedCrossRef
62.
Tamaki N, Yonekura Y, Yamashita K, et al. Positron emission tomography using fluorine-18 deoxyglucose in evaluation of coronary artery bypass grafting. Am J Cardiol 1989;64:860-5.PubMedCrossRef
63.
Maes AF, Borgers M, Flameng W, et al. Assessment of myocardial viability in chronic coronary artery disease using technetium-99m sestamibi SPECT. Correlation with histologic and positron emission tomographic studies and functional follow-up. J Am Coll Cardiol 1997;29:62-8.PubMedCrossRef
64.
Gropler RJ, Geltman EM, Sampathkumaran K, et al. Comparison of carbon-11-acetate with fluorine-18-fluorodeoxyglucose for delineating viable myocardium by positron emission tomography. J Am Coll Cardiol 1993;22:1587-97.PubMedCrossRef
65.
Knuuti MJ, Saraste M, Nuutila P, et al. Myocardial viability: Fluorine-18-deoxyglucose positron emission tomography in prediction of wall motion recovery after revascularization. Am Heart J 1994;127:785-96.PubMedCrossRef
66.
Tamaki N, Kawamoto M, Tadamura E, et al. Prediction of reversible ischemia after revascularization. Perfusion and metabolic studies with positron emission tomography. Circulation 1995;91:1697-705.PubMedCrossRef
67.
Baer FM, Voth E, Deutsch HJ, et al. Predictive value of low dose dobutamine transesophageal echocardiography and fluorine-18 fluorodeoxyglucose positron emission tomography for recovery of regional left ventricular function after successful revascularization. J Am Coll Cardiol 1996;28:60-9.PubMedCrossRef
68.
Lucignani G, Paolini G, Landoni C, et al. Presurgical identification of hibernating myocardium by combined use of technetium-99m hexakis 2-methoxyisobutylisonitrile single photon emission tomography and fluorine-18 fluoro-2-deoxy-d-glucose positron emission tomography in patients with coronary artery disease. Eur J Nucl Med 1992;19:874-81.PubMedCrossRef
69.
Carrel T, Jenni R, Haubold-Reuter S, von Schulthess G, Pasic M, Turina M. Improvement of severely reduced left ventricular function after surgical revascularization in patients with preoperative myocardial infarction. Eur J Cardiothorac Surg 1992;6:479-84.PubMedCrossRef
70.
Tamaki N, Ohtani H, Yamashita K, et al. Metabolic activity in the areas of new fill-in after thallium-201 reinjection: Comparison with positron emission tomography using fluorine-18-deoxyglucose. J Nucl Med 1991;32:673-8.PubMed
71.
Bax JJ, Cornel JH, Visser FC, et al. Prediction of recovery of myocardial dysfunction after revascularization. Comparison of fluorine-18 fluorodeoxyglucose/thallium-201 SPECT, thallium-201 stress-reinjection SPECT and dobutamine echocardiography. J Am Coll Cardiol 1996;28:558-64.PubMedCrossRef
72.
Dilsizian V, Rocco TP, Freedman NM, Leon MB, Bonow RO. Enhanced detection of ischemic but viable myocardium by the reinjection of thallium after stress-redistribution imaging. N Engl J Med 1990;323:141-6.PubMedCrossRef
73.
Ohtani H, Tamaki N, Yonekura Y, et al. Value of thallium-201 reinjection after delayed SPECT imaging for predicting reversible ischemia after coronary artery bypass grafting. Am J Cardiol 1990;66:394-9.PubMedCrossRef
74.
Arnese M, Cornel JH, Salustri A, et al. Prediction of improvement of regional left ventricular function after surgical revascularization. A comparison of low-dose dobutamine echocardiography with 201Tl single-photon emission computed tomography. Circulation 1995;91:2748-52.PubMedCrossRef
75.
Haque T, Furukawa T, Takahashi M, Kinoshita M. Identification of hibernating myocardium by dobutamine stress echocardiography: Comparison with thallium-201 reinjection imaging. Am Heart J 1995;130:553-63.PubMedCrossRef
76.
Vanoverschelde JL, D’Hondt AM, Marwick T, et al. Head-to-head comparison of exercise-redistribution-reinjection thallium single-photon emission computed tomography and low dose dobutamine echocardiography for prediction of reversibility of chronic left ventricular ischemic dysfunction. J Am Coll Cardiol 1996;28:432-42.PubMed
77.
Marzullo P, Parodi O, Reisenhofer B, et al. Value of rest thallium-201/technetium-99m sestamibi scans and dobutamine echocardiography for detecting myocardial viability. Am J Cardiol 1993;71:166-72.PubMedCrossRef
78.
Udelson JE, Coleman PS, Metherall J, et al. Predicting recovery of severe regional ventricular dysfunction. Comparison of resting scintigraphy with 201Tl and 99mTc-sestamibi. Circulation 1994;89:2552-61.PubMedCrossRef
79.
Alfieri O, La Canna G, Giubbini R, Pardini A, Zogno M, Fucci C. Recovery of myocardial function. The ultimate target of coronary revascularization. Eur J Cardiothorac Surg 1993;7:325-30 discussion 330.PubMedCrossRef
80.
Charney R, Schwinger ME, Chun J, et al. Dobutamine echocardiography and resting-redistribution thallium-201 scintigraphy predicts recovery of hibernating myocardium after coronary revascularization. Am Heart J 1994;128:864-9.PubMedCrossRef
81.
Perrone-Filardi P, Pace L, Prastaro M, et al. Assessment of myocardial viability in patients with chronic coronary artery disease. Rest-4-hour-24-hour 201Tl tomography versus dobutamine echocardiography. Circulation 1996;94:2712-9.PubMedCrossRef
82.
Qureshi U, Nagueh SF, Afridi I, et al. Dobutamine echocardiography and quantitative rest-redistribution 201Tl tomography in myocardial hibernation. Relation of contractile reserve to 201Tl uptake and comparative prediction of recovery of function. Circulation 1997;95:626-35.PubMedCrossRef
83.
Marzullo P, Sambuceti G, Parodi O, et al. Regional concordance and discordance between rest thallium 201 and sestamibi imaging for assessing tissue viability: Comparison with postrevascularization functional recovery. J Nucl Cardiol 1995;2:309-16.PubMedCrossRef
84.
Gonzalez P, Massardo T, Munoz A, et al. Is the addition of ECG gating to technetium-99m sestamibi SPET of value in the assessment of myocardial viability? An evaluation based on two-dimensional echocardiography following revascularization. Eur J Nucl Med 1996;23:1315-22.PubMedCrossRef
85.
Marzullo P, Sambuceti G, Parodi O. The role of sestamibi scintigraphy in the radioisotopic assessment of myocardial viability. J Nucl Med 1992;33:1925-30.PubMed
86.
Maublant JC, Citron B, Lipiecki J, et al. Rest technetium 99m-sestamibi tomoscintigraphy in hibernating myocardium. Am Heart J 1995;129:306-14.PubMedCrossRef
87.
Bisi G, Sciagra R, Santoro GM, Fazzini PF. Rest technetium-99m sestamibi tomography in combination with short-term administration of nitrates: Feasibility and reliability for prediction of postrevascularization outcome of asynergic territories. J Am Coll Cardiol 1994;24:1282-9.PubMedCrossRef
88.
Maurea S, Cuocolo A, Soricelli A, et al. Myocardial viability index in chronic coronary artery disease: Technetium-99m-methoxy isobutyl isonitrile redistribution. J Nucl Med 1995;36:1953-60.PubMed
89.
Bisi G, Sciagra R, Santoro GM, Rossi V, Fazzini PF. Technetium-99m-sestamibi imaging with nitrate infusion to detect viable hibernating myocardium and predict postrevascularization recovery. J Nucl Med 1995;36:1994-2000.PubMed
90.
Afridi I, Kleiman NS, Raizner AE, Zoghbi WA. Dobutamine echocardiography in myocardial hibernation. Optimal dose and accuracy in predicting recovery of ventricular function after coronary angioplasty. Circulation 1995;91:663-70.PubMedCrossRef
91.
Senior R, Raval U, Lahiri A. Technetium 99m-labeled sestamibi imaging reliably identifies retained contractile reserve in dyssynergic myocardial segments. J Nucl Cardiol 1995;2:296-302.PubMedCrossRef
92.
La Canna G, Alfieri O, Giubbini R, Gargano M, Ferrari R, Visioli O. Echocardiography during infusion of dobutamine for identification of reversibly dysfunction in patients with chronic coronary artery disease. J Am Coll Cardiol 1994;23:617-26.PubMedCrossRef
93.
Perrone-Filardi P, Pace L, Prastaro M, et al. Dobutamine echocardiography predicts improvement of hypoperfused dysfunctional myocardium after revascularization in patients with coronary artery disease. Circulation 1995;91:2556-65.PubMedCrossRef
94.
deFilippi CR, Willett DL, Irani WN, Eichhorn EJ, Velasco CE, Grayburn PA. Comparison of myocardial contrast echocardiography and low-dose dobutamine stress echocardiography in predicting recovery of left ventricular function after coronary revascularization in chronic ischemic heart disease. Circulation 1995;92:2863-8.PubMedCrossRef
95.
Bax JJ, Poldermans D, Elhendy A, Boersma E, Rahimtoola SH. Sensitivity, specificity, and predictive accuracies of various noninvasive techniques for detecting hibernating myocardium. Curr Probl Cardiol 2001;26:147-86.PubMedCrossRef
96.
Schinkel AF, Bax JJ, Poldermans D, Elhendy A, Ferrari R, Rahimtoola SH. Hibernating myocardium: Diagnosis and patient outcomes. Curr Probl Cardiol 2007;32:375-410.PubMedCrossRef
97.
Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: A meta-analysis. J Am Coll Cardiol 2002;39:1151-8.PubMedCrossRef
98.
Tamaki N, Kawamoto M, Takahashi N, et al. Prognostic value of an increase in fluorine-18 deoxyglucose uptake in patients with myocardial infarction: Comparison with stress thallium imaging. J Am Coll Cardiol 1993;22:1621-7.PubMedCrossRef
99.
Yoshida K, Gould KL. Quantitative relation of myocardial infarct size and myocardial viability by positron emission tomography to left ventricular ejection fraction and 3-year mortality with and without revascularization. J Am Coll Cardiol 1993;22:984-97.PubMedCrossRef
100.
Di Carli MF, Davidson M, Little R, et al. Value of metabolic imaging with positron emission tomography for evaluating prognosis in patients with coronary artery disease and left ventricular dysfunction. Am J Cardiol 1994;73:527-33.PubMedCrossRef
101.
Dreyfus GD, Duboc D, Blasco A, et al. Myocardial viability assessment in ischemic cardiomyopathy: Benefits of coronary revascularization. Ann Thorac Surg 1994;57:1402-7.PubMedCrossRef
102.
Lee KS, Marwick TH, Cook SA, et al. Prognosis of patients with left ventricular dysfunction, with and without viable myocardium after myocardial infarction. Relative efficacy of medical therapy and revascularization. Circulation 1994;90:2687-94.CrossRefPubMed
103.
G. Gioia, J. Powers, J. Heo, A.S. Iskandrian. Prognostic value of rest-redistribution tomographic thallium-201 imaging in ischemic cardiomyopathy. Am J Cardiol 1995;75:759-62. ISSN: 0002-9149.
104.
Gioia G, Milan E, Giubbini R, DePace N, Heo J, Iskandrian AS. Prognostic value of tomographic rest-redistribution thallium 201 imaging in medically treated patients with coronary artery disease and left ventricular dysfunction. J Nucl Cardiol 1996;3:150-6.PubMedCrossRef
105.
Williams MJ, Odabashian J, Lauer MS, Thomas JD, Marwick TH. Prognostic value of dobutamine echocardiography in patients with left ventricular dysfunction. J Am Coll Cardiol 1996;27:132-9.PubMedCrossRef
106.
Haas F, Haehnel CJ, Picker W, et al. Preoperative positron emission tomographic viability assessment and perioperative and postoperative risk in patients with advanced ischemic heart disease. J Am Coll Cardiol 1997;30:1693-700.PubMedCrossRef
107.
Pagley PR, Beller GA, Watson DD, Gimple LW, Ragosta M. Improved outcome after coronary bypass surgery in patients with ischemic cardiomyopathy and residual myocardial viability. Circulation 1997;96:793-800.PubMedCrossRef
108.
Petretta M, Cuocolo A, Bonaduce D, et al. Incremental prognostic value of thallium reinjection after stress-redistribution imaging in patients with previous myocardial infarction and left ventricular dysfunction. J Nucl Med 1997;38:195-200.PubMed
109.
vom Dahl J, Altehoefer C, Sheehan FH, et al. Effect of myocardial viability assessed by technetium-99m-sestamibi SPECT and fluorine-18-FDG PET on clinical outcome in coronary artery disease. J Nucl Med 1997;38:742-8.PubMed
110.
Afridi I, Grayburn PA, Panza JA, Oh JK, Zoghbi WA, Marwick TH. Myocardial viability during dobutamine echocardiography predicts survival in patients with coronary artery disease and severe left ventricular systolic dysfunction. J Am Coll Cardiol 1998;32:921-6.PubMedCrossRef
111.
Anselmi M, Golia G, Cicoira M, et al. Prognostic value of detection of myocardial viability using low-dose dobutamine echocardiography in infarcted patients. Am J Cardiol 1998;81:21G-8G.CrossRefPubMed
112.
Beanlands RS, Hendry PJ, Masters RG, deKemp RA, Woodend K, Ruddy TD. Delay in revascularization is associated with increased mortality rate in patients with severe left ventricular dysfunction and viable myocardium on fluorine 18-fluorodeoxyglucose positron emission tomography imaging. Circulation 1998;98:II51-6.
113.
Cuocolo A, Petretta M, Nicolai E, et al. Successful coronary revascularization improves prognosis in patients with previous myocardial infarction and evidence of viable myocardium at thallium-201 imaging. Eur J Nucl Med 1998;25:60-8.PubMedCrossRef
114.
Di Carli MF, Maddahi J, Rokhsar S, et al. Long-term survival of patients with coronary artery disease and left ventricular dysfunction: Implications for the role of myocardial viability assessment in management decisions. J Thorac Cardiovasc Surg 1998;116:997-1004.PubMedCrossRef
115.
Huitink JM, Visser FC, Bax JJ, et al. Predictive value of planar 18F-fluorodeoxyglucose imaging for cardiac events in patients after acute myocardial infarction. Am J Cardiol 1998;81:1072-7.PubMedCrossRef
116.
Meluzin J, Cerny J, Frelich M, et al. Prognostic value of the amount of dysfunctional but viable myocardium in revascularized patients with coronary artery disease and left ventricular dysfunction. Investigators of this multicenter study. J Am Coll Cardiol 1998;32:912-20.PubMedCrossRef
117.
Pagano D, Bonser RS, Townend JN, Ordoubadi F, Lorenzoni R, Camici PG. Predictive value of dobutamine echocardiography and positron emission tomography in identifying hibernating myocardium in patients with postischaemic heart failure. Heart 1998;79:281-8.PubMed
118.
Bax JJ, Poldermans D, Elhendy A, et al. Improvement of left ventricular ejection fraction, heart failure symptoms and prognosis after revascularization in patients with chronic coronary artery disease and viable myocardium detected by dobutamine stress echocardiography. J Am Coll Cardiol 1999;34:163-9.PubMedCrossRef
119.
Pasquet A, Robert A, D’Hondt AM, Dion R, Melin JA, Vanoverschelde JL. Prognostic value of myocardial ischemia and viability in patients with chronic left ventricular ischemic dysfunction. Circulation 1999;100:141-8.PubMedCrossRef
120.
Senior R, Kaul S, Lahiri A. Myocardial viability on echocardiography predicts long-term survival after revascularization in patients with ischemic congestive heart failure. J Am Coll Cardiol 1999;33:1848-54.PubMedCrossRef
121.
Smart SC, Dionisopoulos PN, Knickelbine TA, Schuchard T, Sagar KB. Dobutamine-atropine stress echocardiography for risk stratification in patients with chronic left ventricular dysfunction. J Am Coll Cardiol 1999;33:512-21.PubMedCrossRef
122.
Bonow RO. Myocardial viability and prognosis in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol 2002;39:1159-62.PubMedCrossRef
123.
Beller GA, Budge LP. Viable: Yes, no, or somewhere in the middle? JACC Cardiovasc Imaging 2009;2:1069-71.PubMedCrossRef
124.
Bourque JM, Hasselblad V, Velazquez EJ, Borges-Neto S, O’Connor CM. Revascularization in patients with coronary artery disease, left ventricular dysfunction, and viability: A meta-analysis. Am Heart J 2003;146:621-7.PubMedCrossRef
125.
Camici PG, Prasad SK, Rimoldi OE. Stunning, hibernation, and assessment of myocardial viability. Circulation 2008;117:103-14.PubMedCrossRef
126.
Kwong RY, Sattar H, Wu H, et al. Incidence and prognostic implication of unrecognized myocardial scar characterized by cardiac magnetic resonance in diabetic patients without clinical evidence of myocardial infarction. Circulation 2008;118:1011-20.PubMedCrossRef
127.
Cheong BY, Muthupillai R, Wilson JM, et al. Prognostic significance of delayed-enhancement magnetic resonance imaging: Survival of 857 patients with and without left ventricular dysfunction. Circulation 2009;120:2069-76.PubMedCrossRef
128.
Kwon DH, Halley CM, Carrigan TP, et al. Extent of left ventricular scar predicts outcomes in ischemic cardiomyopathy patients with significantly reduced systolic function: a delayed hyperenhancement cardiac magnetic resonance study. JACC Cardiovasc Imaging 2009;2:34-44.PubMedCrossRef
129.
Kelle S, Roes SD, Klein C, et al. Prognostic value of myocardial infarct size and contractile reserve using magnetic resonance imaging. J Am Coll Cardiol 2009;54:1770-7.PubMedCrossRef
130.
Romero J, Xue X, Gonzalez W, Garcia MJ. CMR imaging assessing viability in patients with chronic ventricular dysfunction due to coronary artery disease: A meta-analysis of prospective trials. JACC Cardiovasc Imaging 2012;5:494-508.PubMedCrossRef
131.
Bove CM, DiMaria JM, Voros S, Conaway MR, Kramer CM. Dobutamine response and myocardial infarct transmurality: functional improvement after coronary artery bypass grafting—Initial experience. Radiology 2006;240:835-41.PubMedCrossRef
132.
Schuster A, Morton G, Chiribiri A, Perera D, Vanoverschelde JL, Nagel E. Imaging in the management of ischemic cardiomyopathy: Special focus on magnetic resonance. J Am Coll Cardiol 2012;59:359-70.PubMedCrossRef
133.
Cleland JG, Pennel D, Ray S, et al. The carvedilol hibernation reversible ischaemia trial; marker of success (CHRISTMAS). The CHRISTMAS Study Steering Committee and Investigators. Eur J Heart Fail 1999;1:191-6.PubMedCrossRef
134.
Abraham A, Nichol G, Williams KA, et al. 18F-FDG PET imaging of myocardial viability in an experienced center with access to 18F-FDG and integration with clinical management teams: The Ottawa-FIVE substudy of the PARR 2 trial. J Nucl Med 2010;51:567-74.PubMedCrossRef
135.
Hillis GS, Zehr KJ, Williams AW, et al. Outcome of patients with low ejection fraction undergoing coronary artery bypass grafting: Renal function and mortality after 3.8 years. Circulation 2006;114:I414-9.PubMedCrossRef
136.
Cooper WA, O’Brien SM, Thourani VH, et al. Impact of renal dysfunction on outcomes of coronary artery bypass surgery: Results from the Society of Thoracic Surgeons National Adult Cardiac Database. Circulation 2006;113:1063-70.PubMedCrossRef
137.
Cleland JG, Freemantle N, Ball SG, et al. The heart failure revascularisation trial (HEART): Rationale, design and methodology. Eur J Heart Fail 2003;5:295-303.PubMedCrossRef
138.
Cleland JG, Calvert M, Freemantle N, et al. The heart failure revascularisation trial (HEART). Eur J Heart Fail 2010;13:227-33.PubMedCrossRef
139.
140.
Velazquez EJ, Lee KL, O’Connor CM, et al. The rationale and design of the surgical treatment for ischemic heart failure (STICH) trial. J Thorac Cardiovasc Surg 2007;134:1540-7.PubMedCrossRef
141.
Jones RH, Velazquez EJ, Michler RE, et al. Coronary bypass surgery with or without surgical ventricular reconstruction. N Engl J Med 2009;360:1705-17.PubMedCrossRef
142.
Mark DB, Knight JD, Velazquez EJ et al. Quality of life and economic outcomes with surgical ventricular reconstruction in ischemic heart failure: Results from the surgical treatment for ischemic heart failure trial. Am Heart J 2009;157:837-44, 844 e1-3.
143.
Jones RH, White H, Velazquez EJ, et al. STICH (surgical treatment for ischemic heart failure) trial enrollment. J Am Coll Cardiol 2010;56:490-8.PubMedCrossRef
144.
Zembala M, Michler RE, Rynkiewicz A, et al. Clinical characteristics of patients undergoing surgical ventricular reconstruction by choice and by randomization. J Am Coll Cardiol 2010;56:499-507.PubMedCrossRef
145.
Bonow RO, Maurer G, Lee KL, et al. Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med 2011;364:1617-25.PubMedCrossRef
146.
Velazquez EJ, Lee KL, Deja MA, et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med 2011;364:1607-16.PubMedCrossRef
147.
Oh JK, Pellikka PA, Panza JA, et al. Core lab analysis of baseline echocardiographic studies in the STICH trial and recommendation for use of echocardiography in future clinical trials. J Am Soc Echocardiogr 2012;25:327-36.PubMedCrossRef
148.
Deja MA, Grayburn PA, Sun B, et al. Influence of mitral regurgitation repair on survival in the surgical treatment for ischemic heart failure trial. Circulation 2012;125:2639-48.PubMedCrossRef
149.
Michler RE, Rouleau JL, Al-Khalidi HR et al. Insights from the STICH trial: Change in left ventricular size after coronary artery bypass grafting with and without surgical ventricular reconstruction. J Thorac Cardiovasc Surg 2012. doi:10.​1016/​j.​jtcvs.​2012.​09.​007.
150.
Oh JK, Velazquez EJ, Menicanti L, et al. Influence of baseline left ventricular function on the clinical outcome of surgical ventricular reconstruction in patients with ischaemic cardiomyopathy. Eur Heart J 2013;34:39-47.PubMedCrossRef
151.
Panza JA, Holly TA, Asch FM, et al. Inducible myocardial ischemia and outcomes in patients with coronary artery disease and left ventricular dysfunction. J Am Coll Cardiol 2013;61:1860-70.PubMedCrossRef
152.
Chareonthaitawee P, Gersh BJ, Panza JA. Is viability imaging still relevant in 2012? JACC Cardiovasc Imaging 2012;5:550-8.PubMedCrossRef
153.
Perrone-Filardi P, Pinto FJ. Looking for myocardial viability after a STICH trial: Not enough to close the door. J Nucl Med 2012;53:349-52.PubMedCrossRef
154.
Kramer CM, Narula J. Viability is in the eye of the beholder. JACC Cardiovasc Imaging 2012;5:574-5.PubMedCrossRef
155.
Asrani NS, Chareonthaitawee P, Pellikka PA. Viability by MRI or PET would not have changed the results of the STICH trial. Prog Cardiovasc Dis 2013;55:494-7.PubMedCrossRef
156.
Cortigiani L, Bigi R, Sicari R. Is viability still viable after the STICH trial? Eur Heart J Cardiovasc Imaging 2012;13:219-26.PubMedCrossRef
157.
Rouleau JL, Michler RE, Velazquez EJ, et al. The STICH trial: Evidence-based conclusions. Eur J Heart Fail 2010;12:1028-30.PubMedCrossRef
158.
Daggubati R, Arumugham P, Ferguson TB Jr. The world post STICH: Is this a “game changer?” A surgeon’s perspective—Revascularization is still the treatment of choice. Prog Cardiovasc Dis 2013;55:470-5.PubMedCrossRef
159.
Elamm C, Fang JC. The world post-STICH: Is this a “game changer?” A non-invasive cardiologist’s perspective—Revascularization is the treatment of choice only in patients who fail medical therapy. Prog Cardiovasc Dis 2013;55:466-9.PubMedCrossRef
160.
Shah BN, Khattar RS, Senior R. The hibernating myocardium: Current concepts, diagnostic dilemmas, and clinical challenges in the post-STICH era. Eur Heart J 2013;34:1323-36.PubMedCrossRef
161.
Whayne TF, Jr, Saha SP, Quevedo K, Mukherjee D. Optimal medical therapy for coronary artery disease in 2011—Perspectives from the STICH trial. Cardiovasc Hematol Agents Med Chem 2011;9:269-76.
162.
Srichai MB, Jaber WA. Viability by MRI or PET would have changed the results of the STICH trial. Prog Cardiovasc Dis 2013;55:487-93.PubMedCrossRef
163.
164.
Shaw LJ, Cerqueira MD, Brooks MM, et al. Impact of left ventricular function and the extent of ischemia and scar by stress myocardial perfusion imaging on prognosis and therapeutic risk reduction in diabetic patients with coronary artery disease: Results from the bypass angioplasty revascularization investigation 2 diabetes (BARI 2D) trial. J Nucl Cardiol 2012;19:658-69.PubMedCrossRef
165.
le Polain de Waroux JB, Pouleur AC, Vancraeynest D, et al. Early hazards of mitral ring annuloplasty in patients with moderate to severe ischemic mitral regurgitation undergoing coronary revascularization: The importance of preoperative myocardial viability. J Heart Valve Dis 2009;18:35-43.PubMed
166.
Pu M, Thomas JD, Gillinov MA, Griffin BP, Brunken RC. Importance of ischemic and viable myocardium for patients with chronic ischemic mitral regurgitation and left ventricular dysfunction. Am J Cardiol 2003;92:862-4.PubMedCrossRef
167.
Santana CA, Shaw LJ, Garcia EV, et al. Incremental prognostic value of left ventricular function by myocardial ECG-gated FDG PET imaging in patients with ischemic cardiomyopathy. J Nucl Cardiol 2004;11:542-50.PubMedCrossRef
168.
Allman KC. 18F-FDG PET and myocardial viability assessment: Trials and tribulations. J Nucl Med 2010;51:505-6.PubMedCrossRef
169.
Iskandrian AE, Hage FG. Towards personalized myocardial viability testing: Personal reflections. J Nucl Cardiol 2012;19:216-9.PubMedCrossRef
170.
Luisi AJ Jr, Suzuki G, Dekemp R, et al. Regional 11C-hydroxyephedrine retention in hibernating myocardium: Chronic inhomogeneity of sympathetic innervation in the absence of infarction. J Nucl Med 2005;46:1368-74.PubMed
171.
172.
Maddahi J. Viability assessment with MRI is superior to FDG-PET for viability: Pro. J Nucl Cardiol 2010;17:292-7.PubMedCrossRef
173.
Beller GA. The case for cardiac magnetic resonance and positron emission tomography multimodality imaging of myocardial viability. J Nucl Cardiol 2010;17:527-8.PubMedCrossRef
174.
Kuhl HP, Lipke CS, Krombach GA, et al. Assessment of reversible myocardial dysfunction in chronic ischaemic heart disease: Comparison of contrast-enhanced cardiovascular magnetic resonance and a combined positron emission tomography-single photon emission computed tomography imaging protocol. Eur Heart J 2006;27:846-53.PubMedCrossRef
175.
Rischpler C, Nekolla SG, Dregely I, Schwaiger M. Hybrid PET/MR imaging of the heart: Potential, initial experiences, and future prospects. J Nucl Med 2013;54:402-15.PubMedCrossRef
176.
Metadata
Title
Noninvasive assessment myocardial viability: Current status and future directions
Author
Kevin C. Allman, MBBS, FRACP, FACC, FCSANZ, FAANMS, FASNC
Publication date
01-08-2013
Publisher
Springer US
Published in
Journal of Nuclear Cardiology / Issue 4/2013
Print ISSN: 1071-3581
Electronic ISSN: 1532-6551
DOI
https://doi.org/10.1007/s12350-013-9737-8

Other articles of this Issue 4/2013

Journal of Nuclear Cardiology 4/2013 Go to the issue

Original Article

Diagnostic sensitivity of SPECT myocardial perfusion imaging using a pumping cardiac phantom with inserted variable defects

News

CME instructions: Noninvasive assessment myocardial viability: Current status and future directions

Letter to the Editor

Reply: Correlation between clinical outcomes and appropriateness grading for referral to myocardial perfusion imaging for preoperative evaluation prior to non-cardiac surgery

Review Article

Angiographic correlation of myocardial perfusion imaging with half the radiation dose using ordered-subset expectation maximization with resolution recovery software

Original Article

The prognostic value of cardiac SPECT performed at the primary care physician’s office

Editor's Page

Our health system and the poorest Americans

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits